Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C1S | P09871 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25048576 | 1.00 | C1S (0.33) | C1SCA2DRD2DRD4DRD3 | |
| SCHEMBL25048476 | 1.00 | C1S (0.33) | C1SCA2DRD2DRD4DRD3 | |
| SCHEMBL30940995 | 1.00 | C1S (0.33) | C1SCA2DRD2DRD4DRD3 | |
| SCHEMBL25048499 | 0.91 | C1S (0.34) | C1SCA2 | |
| SCHEMBL25047781 | 0.88 | AXL (0.33) | DRD2DRD4DRD3 | |
| SCHEMBL30941162 | 0.88 | AXL (0.33) | DRD2DRD4DRD3 | |
| SCHEMBL25047793 | 0.87 | C1S (0.33) | C1SCA2DRD2DRD4DRD3 | |
| SCHEMBL25047795 | 0.87 | C1S (0.33) | C1SCA2 | |
| SCHEMBL25047889 | 0.86 | IGF1R (0.32) | C1SCA2DRD2DRD4DRD3 | |
| SCHEMBL25048724 | 0.86 | C1S (0.31) | C1SCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | C1S 1866/4885CA2 3376/4885DRD2 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.